[ad_1]
The European Medicines Agency (EMA) presented its findings to the European Commission, which asked it to assess fears that several countries are only vaccinating the elderly with this vaccine.
“The benefits of vaccination have been found to increase with age and incidence,” the Amsterdam-based EVA said in a statement.
The benefits of Vaxzevria outweigh the risks in all adult age groups, although very rare cases of blood clots with decreased platelets have been reported after vaccination, ”the agency said, citing the name of the product developed by AstraZeneca and the University. from Oxford.
Public confidence in AstraZeneca has been affected by EVA’s announcement on April 7 that very rare but often fatal blood clots can be one of the side effects of the vaccine.
Earlier this week, the EVA reported that rare blood clots are also identified as a possible side effect of the J&J vaccine. Both vaccines have been developed using similar adenoviral vector technology.
[ad_2]
